Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status

Background Human epidermal growth factor receptor 2 (HER2)-low status has recently gained attention because of the potential therapeutic benefits of antibody–drug conjugates (ADCs) in breast cancer patients. We aimed to investigate the concordance of HER2 status between core needle biopsy (CNB) and subsequent surgical resection specimens focusing on the HER2-low status. Methods This retrospective study was conducted in 1,387 patients with invasive breast cancer whose HER2 status was evaluated in both CNB and surgical resection specimens. The discordance rates between CNB and surgical resection specimens and the clinicopathological features associated with HER2 status discordance were analyzed. Results The overall concordance rates of HER2 status between CNB and surgical resection specimens were 99.0% (κ = 0.925) for two-group classification (negative vs. positive) and 78.5% (κ = 0.587) for three-group classification (zero vs. low vs. positive). The largest discordance occurred in CNB-HER2-zero cases with 42.8% of them reclassified as HER2-low in surgical resection. HER2 discordance was associated with lower histologic grade, tumor multiplicity, and luminal A subtype. In multivariate analysis, tumor multiplicity and estrogen receptor (ER) positivity were independent predictive factors for HER2-zero to low conversion. Conclusions Incorporation of HER2-low category in HER2 status interpretation reduces the concordance rate between CNB and surgical resection specimens. Tumor multiplicity and ER positivity are predictive factors for conversion from HER2-zero to HER2-low status. Therefore, HER2 status should be re-evaluated in resection specimens when considering ADCs in tumors exhibiting multiplicity and ER positivity.


Introduction
Breast cancer is a heterogeneous disease, and accurate determination of basic biomarkers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is crucial for selecting appropriate treatment for breast cancer patients.Immunohistochemistry (IHC) and in situ hybridization (ISH) are standard methods for evaluating HER2 status in breast cancer [1].HER2-targeted therapy is exclusively effective in HER2-positive (IHC 3 + and/or ISH-positive) breast cancers which account for 15-20% of invasive breast cancers [2,3].Thus, approximately 80-85% of invasive breast cancers are classified as HER2-negative (IHC 0, IHC 1 + , and IHC 2 + /ISH-negative) and are not eligible for HER2-targeted therapy.
Traditionally, HER2-targeted agents were not applicable for breast cancers with intermediate HER2 expression levels often referred to as HER2-low (IHC 1 + or IHC 2 + /ISH-negative) [4].However, recent observations with novel anti-HER2 compounds suggest that a subset of HER2-low breast cancers may benefit from HER2targeted therapies.For example, the DESTINY-Breast04 trial, an open-label phase III study, showed a significant improvement in survival outcomes among advanced/ metastatic HER2-low breast cancer patients treated with an antibody-drug conjugate (ADC), trastuzumab deruxtecan, compared with those treated with the chemotherapy regimen selected by physicians [5].Subsequently, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) revised their guidelines for HER2 testing.They incorporated footnotes specifically addressing HER2-low tumors to guide identification and treatment of trastuzumab deruxtecan-eligible patients [6].
Core needle biopsy (CNB) is less invasive and more cost-effective than excisional biopsy, and it is currently recommended as the first-line diagnostic modality [7].Many studies have explored the reliability of biomarker testing using CNB compared with ground-truth surgical biomarker results and have reported favorable outcomes [8][9][10].Although evaluation of HER2 status using CNB was considered reliable, such results were based on a binary classification system, which distinguishes HER2positive from HER2-negative tumors [11][12][13].The results may differ when HER2 status is classified as HER2positive, HER2-low, or HER2-zero.Lu et al. observed a decrease in HER2 concordance rate between CNB and surgical resection specimens when incorporating HER2low, with κ value of 0.684 [14].Chen et al. also reported moderate concordance of HER2 status between CNB and surgical resection specimens with three-tiered classification including HER2-low (κ = 0.57) [15].As the current ASCO/CAP guidelines use a 10% cutoff point for HER2 IHC scoring [16], CNB may not represent the HER2 status of the tumor if only a small portion of the tumor shows HER2 staining.Moreover, HER2 staining patterns are not homogeneous in some cases [17,18].Recent studies have reported the limited diagnostic value of CNB in identifying HER2-low breast cancers [14,15].
This study aimed to investigate the concordance of HER2 status between CNB and subsequent surgical resection specimens with a specific focus on the HER2-low status to validate diagnostic accuracy of CNB for determining HER2 status.We also aimed to identify the factors associated with discordance to guide the HER2 re-evaluation in surgical resection specimens.

Patient selection
Data of patients diagnosed with invasive breast cancer who underwent surgery at Seoul National University Bundang Hospital between January 1, 2021, and December 31, 2022, were collected retrospectively.Patients who were histologically diagnosed with invasive breast cancer using CNB and subsequent surgical resection and whose both preoperative CNB and surgical resection specimens were available to standard biomarker testing were eligible for the study.Patients treated with primary systemic therapy (PST) such as neoadjuvant chemotherapy, targeted therapy, or endocrine therapy were excluded.
During this period, 2,243 patients with invasive breast cancer underwent surgery without PST.Of them, 856 patients were excluded due to the following reasons: preoperative histologic confirmation was not performed in 20 patients, CNB results indicated in situ carcinoma or other entities in 199 patients, standard biomarker status was not evaluated preoperatively in 584 patients due to clinician's discretion (in cases of early-stage low-grade breast cancer to expedite surgical resection or biomarker testing done in another institution), the biomarker status was not evaluated in surgical resection specimens in 33 patients, and HER2 ISH was not performed in 20 patients with equivocal (2 +) HER2 IHC result (Fig. 1).Consequently, 1,387 patients were included in the analysis.

Clinicopathological information
Clinical and pathological data were retrieved from the electronic medical records and pathological reports during the study.All CNB and surgical resection specimens were initially diagnosed by experienced breast pathologists.For biopsy specimens, data on the number of tissue cores, histologic subtype (based on the World Health Organization classification criteria), histologic grade (based on the Bloom and Richardson grading system), and the presence or absence of in situ carcinoma were collected.For surgical resection specimens, comprehensive information pertaining to the histological diagnosis, including histologic subtype, tumor size, T stage, N stage, histologic grade, lymphovascular invasion, tumor-infiltrating lymphocytes, and tumor multiplicity, were documented and used for this study.For multifocal or multicentric breast cancer, data of the largest index tumor was used for analyses.Preoperative CNB and surgical resection specimens were matched based on radiologic findings such as size and location.The clinicopathological characteristics of the patients included in this study are summarized in Table 1.
HER2 IHC status was determined according to the 2018 ASCO/CAP guideline: 0, no staining observed or incomplete membrane staining of weak intensity within ≤ 10% of tumor cells; 1 + , incomplete membrane staining of weak intensity in > 10% of tumor cells; 2 + , weak to moderate, complete membranous staining in > 10% of the tumor cells; and 3 + , complete and intense circumferential membrane staining in > 10% of tumor cells.For HER2 equivocal (2 +) cases, HER2 silver ISH (SISH) was performed using INFORM HER2 DNA and chromosome 17 probes (Ventana Medical Systems).HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number ≥ 4.0 per cell was defined as HER2 SISH-positive.HER2/CEP17 ratio of < 2.0 and an average HER2 copy number of < 4.0 per cell was defined as HER2 SISH-negative.In other circumstances, HER2 IHC was reviewed with SISH, and the final HER2 status was assigned in accordance with the 2018 ASCO/CAP guidelines [16].There has been no change in staining protocol for HER2 IHC using 4B5 clone in our country, that was recently reported in Japan [19].

Statistical analysis
SPSS version 26.0.0 for Windows (IBM Corporation, New York, USA) was used for statistical analyses.Pearson's Chi-square test was used to compare the clinicopathological characteristics according to HER2 status.Corrections for multiple testing were performed using the Bonferroni method, and the adjusted p values were calculated.The concordance rates between the HER2 statuses of CNB and surgical resection specimens were analyzed using kappa statistics.Pearson's Chi-square test was used to compare the clinicopathological parameters associated with discordance in HER2 status between CNB and surgical resection specimens.The differences in the number of CNB cores and tumor sizes were analyzed using independent sample t-tests.Logistic regression analysis using a backward stepwise selection method was used to analyze the factors associated with the conversion of HER2-zero to HER2-low status in the resected specimens.The odds ratios (OR) and 95% confidence intervals (CIs) were calculated for significant variables.All p values were two-sided, and p values less than 0.05 were considered statistically significant.

CNB-surgical resection concordance of HER2 status
Using a binary classification of the HER2-negative and HER2-positive groups, the overall concordance rate was 99.0% (1,373/1,387) with a kappa coefficient of 0.925 (p < 0.001; Table 2).Of the 1291 cases with HER2-negative results on CNB, 11 cases were HER2-positive in subsequent surgical resection specimens.Of these, three cases showed HER2 heterogeneity in the surgically resected specimen.Among 96 cases which were HER2-positive on CNB, three were eventually classified as HER2-negative in the surgical resection specimen, and all of them were reported to have low levels of HER2 amplification in the CNB specimens.
Based on the three-group classification system (HER2zero, low, and positive), the overall concordance rate was 78.5% (1,089/1,387) with a kappa coefficient of 0.587 (p < 0.001), indicating moderate consistency (Table 2; Fig. 2).The greatest discordance was reported in CNB-HER2-zero cases of which 42.8% (213/498) were later revealed to have a HER2-low status in the surgical resection specimens.The second-largest discordance was observed in CNB-HER2-low cases where 9.0% (71/793) was found to be HER2-zero in the surgical resection specimens.

Parameters associated with HER2 discordance
According to the three-group classification system, 298 cases (21.5%) showed discordance in HER2 status between CNB and subsequent surgical resection specimens (Fig. 3).We analyzed the clinicopathological parameters associated with discordance in HER2 status between CNB and surgical resection specimens (Table 3).Compared to the concordant cases, the discordant cases had a lower histologic grade (p = 0.014), more multiplicity (p < 0.001), and higher rate of the luminal A subtype (p = 0.035).Hormone receptor status and Ki-67 proliferation index did not reveal a significant association.Considering the tendency of CNB-HER2-zero tumors to be reclassified as HER2-low on surgical resection specimens, the clinicopathological parameters associated with HER2-zero to low conversion were determined (Table 4).
Tumors with CNB-HER2-zero to surgical resection-HER2low conversion showed younger age at diagnosis, lower histologic grade, and higher rate of tumor multiplicity compared to HER2-zero concordant tumors (p = 0.017, p = 0.001   and p = 0.001, respectively).ER and PR positivity rates were higher (p = 0.001 and p = 0.048, respectively), while Ki-67 proliferation index was lower (p = 0.024) in the tumors with HER2-zero to low conversion.

Discussion
This study investigated concordance of HER2 status in 1,387 breast cancer patients with matched CNB-surgical resection specimens.The overall HER2 concordance rate between CNB and surgical resection specimens was excellent when using the conventional two-group classification (99.0%, κ = 0.925) but decreased to 78.5% (κ = 0.587) when using the three-group classification (HER2-zero, HER2low, and HER2-positive).The discrepancy was largest for CNB-HER2-zero cases, in which 42.8% were reclassified as having HER2-low status, largely HER2 IHC 1 + , upon subsequent surgical resection.Conversion of a significant proportion of tumors initially classified as CNB-HER2-zero into HER2-low status on surgical resection can be attributed to the use of the current semi-quantitative HER2 IHC scoring system and heterogeneity of HER2 expression.First, the distinction between HER2 IHC 0 and HER2 IHC 1 + may be arbitrary and vulnerable to inter-observer variation [18].Although Karakas et al. reported a 70% concordance rate between HER2 IHC 0 and 1 + readings [22], Lambein et al. showed that 76% of the local HER2 IHC 0 cases were classified as HER2 IHC 1 + upon central reassessment [23].Criteria adjustment and training, especially in distinguishing between HER2-0 and HER2 IHC 1 + , are essential for increasing the concordance of HER2-low results.Second, since heterogeneous HER2 expression is common in breast cancer [18], if the number of cores in a CNB is insufficient or the tumor is large, the CNB results may not represent the entire tumor.However, our data showed that the number of cores in biopsy specimens and tumor size did not differ between concordant and discordant cases; therefore, the degree of CNB as representative of the entire tumor may have less impact on discordance.
In our study, ER positivity was a characteristic of HER2low breast cancers and was an independent indicator of HER2-zero to low conversion in the resected specimen.Previous studies have consistently reported that HER2low breast cancer is characterized by higher incidence of hormone receptor positivity and luminal subtype [24][25][26].Thus, our finding that ER positivity is a predictive factor for HER2-low status in resection specimens in CNB-HER2-zero cases may indicate that ER positivity is highly associated with HER2-low status.Otherwise, whether ER positivity is associated with increased regional heterogeneity of HER2 expression needs further investigations.In the current study, besides ER/PR positivity, low histologic grade and low Ki-67 proliferation index were associated with HER2low breast cancers.Denkert et al. also reported that HER2low breast cancers tended to show higher hormone receptor expression levels, lower cell proliferation, and lower tumor grade compared to HER2-zero breast cancers in a pooled analysis of 2,310 patients [24].
In this study, we showed that tumor multiplicity was related to HER2 discordance and was an independent predictor of HER2-zero to low conversion in resected specimens.Multicentric tumors (those within different quadrants) and multifocal tumors (those within the same quadrant) are regarded as "multiple breast cancer" if separated by normal or benign breast tissue [27].For these cases, we matched the CNB with the resection specimen by correlating the preoperative radiologic findings such as size and location of tumors with the gross surgical findings.However, we cannot guarantee absolute accuracy of these matches.In addition, some studies reported discrepancies in biomarker status within individual tumors of multiple breast cancer, with discordance in HER2 status observed in 5%-16% of cases [28][29][30].Previously, we observed an inter-lesional heterogeneity in the standard biomarker expression and genomic alterations in a significant proportion of multiple breast cancers despite the histological features of multiple tumors being identical [31].Thus, biomarker testing from one index tumor may not be sufficient to determine the characteristics of a patient's disease and eligibility for targeted therapy.
In our cohort, 70.0% of the patients had HER2-low breast cancer, which was higher than the previously reported 45-55% of breast cancer cases [4].This difference could be attributable to the current treatment standards where patients with HER2-positive breast cancer most likely undergo PST; thus, a portion of them was inevitably excluded in this study.In addition, the fact that even many patients without PST were excluded in our study should be taken into account before drawing any conclusions.
The present study evaluated 1,387 breast cancer patients to elucidate concordance in the HER2 status between CNB and surgical resection specimens, with a focus on the HER2-low status.However, this study has some limitations.First, although HER2 testing and interpretation were performed in accordance with the 2018 updated ASCO/ CAP guidelines and the diagnostic breast pathologists who performed the procedure were sufficiently trained, preanalytic factors such as tissue fixation and cold ischemic time which may affect HER2 IHC status were not considered.Second, although we meticulously matched CNB and surgical resection specimens and exclusively utilized data from the index tumors, it is conceivable that different tumors were inadvertently paired.
In summary, our study confirmed that incorporation of the HER2-low category into HER2 status interpretation in breast cancer resulted in decreased concordance between CNB and surgical resection specimens.Notably, our findings revealed tumor multiplicity and ER positivity as pivotal predictive factors for conversion of HER2-zero status in CNB into HER2-low status in subsequent surgical resection.In clinical practice, our study underscores the need of re-evaluating HER2 status in surgical resection specimens in instances of tumor multiplicity or ER positivity, especially when considering ADC treatment options.Such process is critical in ensuring precise HER2 classification which would in turn, lead to optimal treatment for breast cancer patients.

Fig. 2
Fig. 2 Sankey diagram showing HER2 status concordance between core needle biopsy and surgical resection specimen

Fig. 3
Fig. 3 Histologic and immunohistochemical findings of core needle biopsy (CNB) HER2-zero to surgical resection HER2-low converted cases.A A low-grade invasive breast cancer with HER2 immunohistochemistry (IHC) score 0 in CNB reveals HER2 IHC score 1 + in

Table 1
Clinicopathological characteristics of tumors according to HER2 status

Table 1 (
Numbers in parentheses indicate column percentageP values were calculated by Chi-square test * Corrections for multiple testing were performed with Bonferroni method, and adjusted p values are presented

Table 2
Concordance of HER2 status in CNB and surgical resection specimen